Frequently Asked Questions About CALVENZA™ Vaccines

CALVENZA™ EIV, CALVENZA™ EHV, CALVENZA™ EIV/EHV
Available in 10 dose vials and 1 dose syringes

What makes Calvenza different from other influenza vaccines in the U.S.?

Calvenza incorporates a high antigen mass, flexible administration and a relevant Eurasian A2 influenza strain.These unique features, coupled with an effective adjuvant and a relevant North American A2 influenza strain, make this a very effective influenza vaccine.

Why is a Eurasian Flu strain important in the United States?

Eurasian Flu isolates are the key to providing the broadest influenza protection possible. Given the fact that performance horses travel extensively, it is little wonder that Eurasian influenza isolates have been isolated in North America during the past decade. Experts who survey equine influenza outbreaks around the world and make recommendations to manufacturers have been recommending that North American influenza vaccines include a relevant Eurasian strain for years. Calvenza is the only vaccine approved in the U.S. or Canada that contains both North American and Eurasian strains of influenza A2 viruses.

Does Calvenza EHV protect mares from EHV-1 abortion?

Calvenza has been proven safe for use in pregnant mares and is labeled accordingly. We are aware that some veterinarians have been using Calvenza for prevention of abortion, however, this is an off-label use of the vaccine.

Why give three initial doses of Calvenza?

Independent studies in recent years and experience with intensive vaccination protocols in Europe and elsewhere have shown two-dose protocols to be ineffective in producing immune responses that are consistently effective and long lasting when using killed antigens. Current AAEP vaccination guidelines recommend using a three-dose initial series for all killed vaccines.

Economic considerations sometimes make it difficult to convince clients to give the three initial doses over such a short time period. What should be done in those situations?

We can only recommend that the approved label administration protocol be followed. However, post-license challenge studies for both Calvenza EIV and Calvenza EHV were conducted utilizing a protocol consisting of 2 doses four weeks apart with a third dose administered six months following the second dose. Calvenza vaccines proved very effective when administered in this fashion. This data is available for review by practitioners considering off-label administration schedules.

How long does influenza immunity last with Calvenza?

Duration of immunity challenge studies were conducted by Dr. Jenny Mumford and colleagues at the Animal Health Trust in Newmarket, England. Six and twelve month post vaccination challenge studies resulted in vaccinates demonstrating a significant reduction of severity and incidence of clinical signs, as well as quantity and duration of viral shedding in vaccinates versus non-vaccinated controls following challenge with virulent EIV.

Will I experience site reactions with Calvenza?

Calvenza enjoys a reputation for being very smooth. Field safety trials as well as feedback from clinical usage indicate that a very low incidence of site reactions can be expected when Calvenza is administered I.M.

Can Calvenza be used to booster horses that have been on a regular vaccination schedule with another EIV/EHV vaccine?

With high antigen mass and relevant North American A2 influenza strains, Calvenza should be an ideal vaccine to booster conventional EIV/EHV vaccines. However, the intramuscular route would be recommended for initial booster administrations following other manufacturer's vaccines. Also, the full advantages of Calvenza may not be realized until a series of Calvenza administrations have been completed.

Boehringer Ingelheim

800-325-9167
www.bi-vetmedica.com

BI 1323-15 10/03